Vaginal drug administration in the hospital setting

American Journal of Health-System Pharmacy

Volumn 65, Issue 3, 2008, Pages 254-259

  Das Neves, José ^a,b   Santos, Bárbara ^a,c   Teixeira, Branca ^c   Dias, Gustavo ^c   Cunha, Teresa ^c   Brochado, Jorge ^c,d  

^a UNIVERSITY OF PORTO   (Portugal)

^b HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^c HGSA

^d Portuguese Association of Hospital Pharmacists

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN DERIVATIVE; ETHINYLESTRADIOL PLUS ETONOGESTREL; GESTAGEN; INDOMETACIN; MICONAZOLE; MISOPROSTOL; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E2; SEX HORMONE; SPERMICIDAL AGENT; ULINASTATIN; DRUG;

DRUG DELIVERY SYSTEM; FEMALE; HORMONAL CONTRACEPTION; HORMONE SUBSTITUTION; HUMAN; NOTE; PRIORITY JOURNAL; UROGENITAL TRACT DISEASE; VAGINA RING; ARTICLE; HOSPITAL; INTRAVAGINAL DRUG ADMINISTRATION; METABOLISM; VAGINA;

ADMINISTRATION, INTRAVAGINAL; DRUG DELIVERY SYSTEMS; FEMALE; HOSPITALS; HUMANS; PHARMACEUTICAL PREPARATIONS; VAGINA;

EID: 38749144055     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070093     Document Type: Note

References (73)

1. Macht DI. On the absorption of drugs and poisons through the vagina. J Pharmacol Exp Ther. 1918; 10:509-22.
2. Robinson GD. Absorption from the human vagina. BJOG. 1925; 32:496-504.
3. Johansson ED, Sitruk-Ware R. New delivery systems in contraception: vaginal rings. Am J Obstet Gynecol. 2004; 190:S54-9.
4. Ballagh SA. Vaginal rings for menopausal symptom relief. Drugs Aging. 2004; 21:757-66.
5. Benziger DP, Edelson J. Absorption from the vagina. Drug Metab Rev. 1983; 14:137-68.
6. Stenchever MA, Droegemueller W, Herbst AL et al. Comprehensive gynecology. 4th ed. St. Louis: Mosby; 2001.
7. Bulletti C, de Ziegler D, Flamigni C et al. Targeted drug delivery in gynaecology: the first uterine pass effect. Hum Reprod. 1997; 12:1073-9.
8. Owen DH, Katz DF. A vaginal fluid simulant. Contraception. 1999; 59:91-5.
9. Boskey ER, Cone RA, Whaley KJ et al. Origins of vaginal acidity: high D/L lactate ratio is consistent with bacteria being the primary source. Hum Reprod. 2001; 16:1809-13.
10. Farage M, Maibach H. Lifetime changes in the vulva and vagina. Arch Gynecol Obstet. 2006; 273:195-202.
11. Greendale GA, Lee NP, Arriola ER. The menopause. Lancet. 1999; 353:571-80.
12. Sobel JD. Vaginitis. N Engl J Med. 1997; 337:1896-903.
13. Burruano BT, Schnaare RL, Malamud D. Synthetic cervical mucus formulation. Contraception. 2002; 66:137-40.
14. Hussain A, Ahsan F. The vagina as a route for systemic drug delivery. J Control Release. 2005; 103:301-13.
15. Van der Bijl P, van Eyk AD. Comparative in vitro permeability of human vaginal, small intestinal and colonic mucosa. Int J Pharm. 2003; 261:147-52.
16. Van der Bijl P, Penkler L, van Eyk AD. Permeation of sumatriptan through human vaginal and buccal mucosa. Headache. 2000; 40:137-41.
17. Van der Bijl P, van Eyk AD, Thompson IO. Permeation of 17beta-estradiol through human vaginal and buccal mucosa. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998; 85:393-8.
18. Fisher K, Stiles C, Heim B et al. Can fentanyl be systemically absorbed when administered vaginally? A feasibility study. J Palliat Care. 2006; 22:54-6.
19. Borin MT. Systemic absorption of clindamycin following intravaginal application of clindamycin phosphate 1% cream. J Clin Pharmacol. 1990; 30:33-8.
20. Stevens RE, Konsil J, Verrill SS et al. Bioavailability study of a 1200 mg miconazole nitrate vaginal ovule in healthy female adults. J Clin Pharmacol. 2002; 42:52-60.
21. Merkus JM. Treatment of vaginal candidiasis: orally or vaginally? J Am Acad Dermatol. 1990; 23:568-72.
22. Nappi RE, Liekens G, Brandenburg U. Attitudes, perceptions and knowledge about the vagina: the International Vagina Dialogue Survey. Contraception. 2006; 73:493-500.
23. Vorherr H, Vorherr UF, Mehta P et al. Vaginal absorption of povidone-iodine. JAMA. 1980; 244:2628-9.
24. Strickland DM, Leonard RG, Stavchansky S et al. Vaginal absorption of hexachlorophene during labor. Am J Obstet Gynecol. 1983; 147:769-72.
25. Meadowcroft AM, Diaz PR, Latham GS. Clostridium difficile toxin-induced colitis after use of clindamycin phosphate vaginal cream. Ann Pharmacother. 1998; 32:309-11.
26. Vikenes K, Lund-Tonnesen S, Schreiner A. Clostridium difficile-associated diarrhea after short term vaginal administration of clindamycin. Am J Gastroenterol. 1999; 94:1969-70.
27. Thirion DJ, Zanetti LA. Potentiation of warfarin's hypoprothrombinemic effect with miconazole vaginal suppositories. Pharmacotherapy. 2000; 20:98-9.
28. Wooltorton E. Drug advisory: the interaction between warfarin and vaginal miconazole. Can Med Assoc J. 2001; 165:938. News.
29. Lansdorp D, Bressers HP, Dekens-Konter JA et al. Potentiation of acenocoumarol during vaginal administration of miconazole. Br J Clin Pharmacol. 1999; 47:225-6. Letter.
30. Rock J, Barker RH, Bacon WB. Vaginal absorption of penicillin. Science. 1947; 105:13.
31. Schudmak M, Hesseltine HC. Absorption of penicillin through the human vagina. II. 500,000 units of penicillin at one administration. Am J Obstet Gynecol. 1951; 62:669-71.
32. Ostrop NJ, Lamb J, Reid G. Intravaginal morphine: an alternative route of administration. Pharmacotherapy. 1998; 18:863-5.
33. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003; 362:419-27.
34. Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005; 365:1543-51.
35. Hickey M, Davis SR, Sturdee DW. Treatment of menopausal symptoms: what shall we do now? Lancet. 2005; 366:409-21.
36. Baker VL. Alternatives to oral estrogen replacement. Transdermal patches, percutaneous gels, vaginal creams and rings, implants, other methods of delivery. Obstet Gynecol Clin North Am. 1994; 21:271-97.
37. Cardozo L, Bachmann G, McClish D et al. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol. 1998; 92:722-7.
38. Mor E, Saadat P, Kives S et al. Comparison of vaginal and oral administration of emergency contraception. Fertil Steril. 2005; 84:40-5.
39. Tavaniotou A, Smitz J, Bourgain C et al. Comparison between different routes of progesterone administration as luteal phase support in infertility treatments. Hum Reprod Update. 2000; 6:139-48.
40. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med. 1993; 329:753-6.
41. Margulies M, Campos Perez G, Voto LS. Misoprostol to induce labour. Lancet. 1992; 339:64. Letter.
42. Mackenzie IZ. Induction of labour at the start of the new millennium. Reproduction. 2006; 131:989-98.
43. Kulier R, Gulmezoglu AM, Hofmeyr GJ et al. Medical methods for first trimester abortion. Cochrane Database Syst Rev. 2004:CD002855.
44. Zieman M, Fong SK, Benowitz NL et al. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol. 1997; 90:88-92.
45. Petersen EE, Magnani P. Efficacy and safety of vitamin C vaginal tablets in the treatment of non-specific vaginitis. A randomised, double blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol. 2004; 117:70-5.
46. Fiorilli A, Molteni B, Milani M. Successful treatment of bacterial vaginosis with a policarbophil-carbopol acidic vaginal gel: results from a randomised double-blind, placebo-controlled trial. Eur J Obstet Gynecol Reprod Biol. 2005; 120:202-5.
47. Ginsburg J, Hardiman P, Thomas M. Vaginal bromocriptine. Lancet. 1991; 338:1205-6. Letter.
48. Motta T, de Vincentiis S, Marchini M et al. Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics. Fertil Steril. 1996; 65:440-2.
49. Tasdemir M, Maral I, Tasdemir S et al. Vaginal lisuride for hyperprolactinaemia. Lancet. 1995; 346:1362. Letter.
50. Kanayama N, el Maradny E, Yamamoto N et al. Urinary trypsin inhibitor: a new drug to treat preterm labor: a comparative study with ritodrine. Eur J Obstet Gynecol Reprod Biol. 1996; 67:133-8.
51. Abramov Y, Nadjari M, Weinstein D et al. Indomethacin for preterm labor: a randomized comparison of vaginal and rectal-oral routes. Obstet Gynecol. 2000; 95:482-6.
52. Takeda S, Kuromaki K, Seki H et al. The management of cervical incompetence with protruded membranes into the vagina by vaginal irrigation with granulocyte elastase inhibitor: ulinastatin and PVP-iodine solution. J Obstet Gynaecol. 1997; 17:45-8.
53. Cool-Foley AA, Nathan C, O'Donovan C III et al. Eradication of methicillin-resistant Staphylococcus aureus vaginitis with mupirocin. DICP. 1991; 25: 1331-3.
54. Chen MY, Smith NA, Fox EF et al. Acetarsol pessaries in the treatment of metronidazole resistant Trichomonas vaginalis. Int J STD AIDS. 1999; 10:277-80.
55. Phillips AJ. Treatment of non-albicans Candida vaginitis with amphotericin B vaginal suppositories. Am J Obstet Gynecol. 2005; 192:2009-12; discussion 2012-3.
56. Burman LG, Christensen P, Christensen K et al. Prevention of excess neonatal morbidity associated with group B streptococci by vaginal chlorhexidine disinfection during labour. The Swedish Chlorhexidine Study Group. Lancet. 1992; 340:65-9.
57. Stray-Pedersen B, Bergan T, Hafstad A et al. Vaginal disinfection with chlorhexidine during childbirth. Int J Antimicrob Agents. 1999; 12:245-51.
58. Das Neves J, Amaral MH, Bahia MF. Vaginal drug delivery. In: Gad SC, ed. Pharmaceutical manufacturing handbook. New York: Wiley; 2008.
59. American Society of Hospital Pharmacists. ASHP technical assistance bulletin on compounding nonsterile products in pharmacies. Am J Hosp Pharm. 1994; 51:1441-8.
60. Kastango ES. Blueprint for implementing USP chapter 797 for compounding sterile preparations. Am J Health-Syst Pharm. 2005; 62:1271-88.
61. Das Neves J, Bahia MF. Gels as vaginal drug delivery systems. Int J Pharm. 2006; 318:1-14.
62. Gannon PM, Charest CA, Kasparian SS et al. Prostaglandin E2 vaginal suppositories for cervical ripening: formulation and stability studies. Hosp Pharm. 1995; 30:791-3,796-8,801-2,805.
63. Levinson RS, Mitan SJ, Steinmetz JI et al. An open-label, two-period, crossover study of the systemic bioavailability in healthy women of clindamycin phosphate from two vaginal cream formulations. Clin Ther. 2005; 27:1894-900.
64. Lamp KC, Freeman CD, Klutman NE et al. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet. 1999; 36:353-73.
65. Borin MT, Ryan KK, Hopkins NK. Systemic absorption of clindamycin after intravaginal administration of clindamycin phosphate ovule or cream. J Clin Pharmacol. 1999; 39:805-10.
66. Adachi A, Fukunaga A, Hayashi K et al. Anaphylaxis to polyvinylpyrrolidone after vaginal application of povidoneiodine. Contact Dermatitis. 2003; 48: 133-6.
67. Yanagidate F, Hamaya Y, Dohi S. Vaginal indigo carmine-induced severe hypotension. Anesth Analg. 2001; 92:556-7. Letter.
68. Wu JP, Fielding SL, Fiscella K. The effect of polycarbophil gel (Replens) on bacterial vaginosis: a pilot study. Eur J Obstet Gynecol Reprod Biol. 2007; 130:132-6.
69. Bauer TA, Brown DL, Chai LK. Vaginal misoprostol for term labor induction. Ann Pharmacother. 1997; 31:1391-3.
70. Yilmaz B, Kelekci S, Ertas IE et al. Misoprostol moistened with acetic acid or saline for second trimester pregnancy termination: a randomized prospective double-blind trial. Hum Reprod. 2005; 20:3067-71.
71. Rayburn WF, Powers BL, Plasse TF et al. Pharmacokinetics of a controlled-release misoprostol vaginal insert at term. J Soc Gynecol Investig. 2006; 13:112-7.
72. Bernkop-Schnurch A, Hornof M. Intravaginal drug delivery systems. Am J Drug Del. 2008; 1:241-54.
73. Alexander NJ, Baker E, Kaptein M et al. Why consider vaginal drug administration? Fertil Steril. 2004; 82:1-12.